文献速递核素与放射性配体治疗肿瘤 PET/CT

90Y-FAPI-46放射性药物治疗肉瘤及其他实体瘤的更新队列分析

90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
PubMed 文献 · J Nucl Med · 2026-05-01

该单中心回顾性分析纳入30例经批准治疗耗竭后进展、且68Ga-FAPI-46 PET显示高FAP表达(SUVmax≥10超过50%病灶)的肉瘤或转移性实体瘤患者,于2020年6月至2023年12月接受共77周期90Y-FAPI-46治疗。长期随访确认安全性良好,近半数患者(RECIST疾病控制48%)达疾病稳定,几乎均为肉瘤;PERCIST代谢缓解60%。

要点

  • 90Y-FAPI-46治疗在经治耗竭的高FAP表达肉瘤中显示可控安全性与疾病控制。
  • RECIST疾病控制率48%(12/25),其中部分缓解3例(12%)。
  • PERCIST代谢缓解率60%(12/20),疾病控制与总生存延长相关。

核心结论

  • 长期随访确认90Y-FAPI-46治疗安全性良好,近半数患者达疾病稳定且几乎均为肉瘤,支持FAP靶向放射性药物在转移性肉瘤中的应用。

研究设计与样本

  • 单中心回顾性分析纳入30例经批准治疗耗竭后进展、68Ga-FAPI-46 PET显示高FAP表达(SUVmax≥10且超过50%病灶)的肉瘤或转移性实体瘤患者。

主要发现

  • 30例中肉瘤23例(77%),胰腺癌3例(10%),前列腺癌、胃癌、非黑色素瘤皮肤癌及胆管癌各1例(各3%)。
  • 2020年6月至2023年12月共接受77周期治疗,周期中位间隔5个月(IQR 4个月),11例(37%)接受≥4周期。
  • 首次周期中位给药3.7 GBq(IQR 3.7-3.8 GBq),后续周期中位7.4 GBq(IQR 7.2-7.4 GBq)。
  • 肾脏平均吸收剂量0.48 Gy/GBq(SD 0.06),骨髓0.04 Gy/GBq(SD 0.01),摄取最高病灶平均2.4 Gy/GBq(SD 1.04)。
  • 任何级别血液毒性20/30(67%),≥3级不良事件8/30(27%),包括血小板减少2例(6%)、中性粒细胞减少2例(6%)、贫血2例(6%)、白细胞减少1例(3%)、γ-谷氨酰转移酶升高1例(3%)。

关键数值与推荐

  • RECIST可评估25例,疾病控制率48%(12/25),部分缓解3例(12%)。
  • PERCIST可评估20例,代谢缓解12例(60%)。
  • 疾病控制与总生存延长相关(中位14.6个月 vs 1.9个月)。

临床怎么用

  • 对经批准治疗耗竭、68Ga-FAPI-46 PET显示高FAP表达的转移性肉瘤患者,可考虑90Y-FAPI-46放射性药物治疗。
  • 治疗中需监测血液毒性,并按CTCAE v5.0分级管理不良事件。

局限性

  • 单中心回顾性设计,样本量30例,部分亚组RECIST(n=25)与PERCIST(n=20)可评估例数有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)-46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50% of lesions on 68Ga-FAPI-46 PET). After therapy, 90Y-FAPI-46 scintigraphy confirmed distribution and uptake, and serial 90Y-FAPI-46 PET/CT scans measured absorbed doses. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. Tumor responses were evaluated using RECIST and PERCIST. Results: Thirty patients-23 (77%) with sarcoma, 3 (10%) with pancreatic cancer, 1 (3%) with prostate cancer, 1 (3%) with gastric cancer, 1 (3%) with nonmelanoma skin cancer, and 1 (3%) with cholangiocarcinoma-received a total of 77 cycles of 90Y-FAPI-46 radiopharmaceutical therapy between June 2020 and December 2023 and were followed until death or the last follow-up (April 2024). The median interval between cycles was 5 mo (interquartile range [IQR], 4 mo). Of the 30 patients, 11 (37%) received 4 or more cycles. A median of 3.7 GBq (IQR, 3.7-3.8 GBq) was administered during the first cycle, and a median of 7.4 GBq (IQR, 7.2-7.4 GBq) was administered for subsequent cycles. The mean absorbed dose was 0.48 Gy/GBq (SD, 0.06 Gy/GBq) in the kidneys and 0.04 Gy/GBq (SD, 0.01 Gy/GBq) in the bone marrow. Lesions with the highest uptake absorbed a mean dose of 2.4 Gy/GBq (SD, 1.04 Gy/GBq). After treatment, hematotoxicity of any grade was observed in 20 of 30 (67%) patients. Eight of 30 (27%) patients reached a Common Terminology Criteria for Adverse Events grade of at least 3, experiencing adverse events that included thrombocytopenia in 2 (6%), neutropenia in 2 (6%), anemia in 2 (6%), leukopenia in 1 (3%), and elevated γ-glutamyl transferase in 1 (3%) patient. RECIST (n = 25) and PERCIST (n = 20) responses after treatment were assessed. Disease control according to RECIST was 48% (12/25), including 3 partial responses (12%). Disease control correlated with extended overall survival (median, 14.6 vs. 1.9 mo). Metabolic response per PERCIST was observed in 12 of 20 (60%) patients. Conclusion: With long-term follow-up, the favorable safety profile of 90Y-FAPI-46 therapy is confirmed. Nearly half of the patients demonstrated disease stabilization, almost exclusively in sarcomas. Our findings support the role of FAP-directed radiopharmaceutical therapy in patients with metastatic sarcoma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lanzafame H, Mavroeidi IA, Pabst KM, et al. 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis. J Nucl Med. 2026. PMID: 41714122. doi:10.2967/jnumed.125.271135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。